Type I and type III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 4091-4096

  Santala, Markku ^a   Simojoki, Marja ^a   Risteli, Juha ^a   Risteli, Leila ^a   Kauppila, Antti ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N TERMINAL PEPTIDE; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; PROCOLLAGEN TYPE III N TERMINAL PEPTIDE; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE; TUMOR MARKER;

ARTICLE; CANCER INVASION; CANCER SURVIVAL; COLLAGEN SYNTHESIS; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; ADULT; AGED; BLOOD; CANCER STAGING; CARCINOMA; COMPARATIVE STUDY; FEMALE; FOLLOW UP; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA; COLLAGEN; COLLAGEN TYPE I; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0033233276     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Young, R. C., and Pecorelli, S. Management of early ovarian cancer. Semin. Oncol., 25: 335-339, 1998.
2. McGuire, W. P., and Ozols, R. F. Chemotherapy of advanced ovarian cancer. Semin. Oncol., 25: 340-348, 1998.
3. Makar, A. P. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol., 56: 175-180, 1995.
4. Friedlander, M. L. Prognostic factors in ovarian cancer. Semin. Oncol., 25: 305-314, 1998.
5. Bast, R. C. J., Klug, T. L., St. John, E., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., Zurawski, V. R., and Knapp, R. C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med., 309: 883-887, 1983.
6. Jacobs, I. J., and Bast, R. C. J. The CA 125 tumor-associated antigen: a review of the literature. Hum. Reprod., 4: 1-12, 1989.
7. Risteli, L., Kauppila, A., Mäkilä, U-M., and Risteli, J. Aminoterminal propeptide of type III procollagen in serum: an indicator of intraperitoneal invasion in ovarian cancer? Int. J. Cancer., 41: 409-414, 1988.
8. Zhu, G-G., Risteli, J., Puistola, J., Kauppila, A., and Risteli, L. Progressive ovarian carcinoma induces synthesis of type I and III procollagens in the tumor tissue and peritoneal cavity. Cancer Res., 53: 5028-5032, 1993.
9. Kauppila, S., Saarela, J., Stenbäck, F., Risteli, J., Kauppila, A., and Risteli, L. Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas. Am. J. Pathol., 148: 539-548, 1996.
10. Santala, M., Risteli, J., Risteli, L., Puistola, U., Kacinski, B. M., Stanley, E. R., and Kauppila, A. Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer. Br. J. Cancer., 77: 1825-1831, 1998.
11. Kauppila, A., Puistola, U., Risteli, J., and Risteli, L. Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer. Cancer Res., 49: 1885-1889, 1989.
12. Santala, M., Risteli, L., Puistola, U., Risteli, L., and Kauppila, A. Elevated serum ICTP concentrations reflect poor prognosis in patients with ovarian carcinoma. Ann. Med., 27: 57-61, 1995.
13. Tomás, C., Penttinen, J., Risteli, J., Risteli, L., and Kauppila, A. Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIHNP) in ovarian carcinoma. Ann. Med., 22: 115-121, 1990.
14. Risteli, J., Niemi, S., Trivedi, P., Mäentausta, O., Mowat, A. P., and Risteli, L. Rapid equilibrium radioimmunoassay for the ammo-terminal propeptide of human type III procollagen. Clin. Chem., 34: 715-718, 1988.
15. Risteli, J., Elomaa, I., Niemi, S., Novamo, A., and Risteli, L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin. Chem., 39: 635-640, 1993.
16. Melkko, J., Kauppila, S., Niemi, S., Risteli, L., Haukipuro, K., Jukkola, A., and Risteli, J. Immunoassay for the intact aminoterminal propeptide of human type I procollagen. Clin. Chem., 42: 947-954, 1996.
17. Kaplan, E. L., and Meier, D. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
18. Risteli, J., and Risteli, L. Products of bone collagen metabolism. In: M. J. Seibel, S. P. Robins, and J. P. Bilezikian (eds.), Dynamics of bone and cartilage metabolism: principles and clinical applications. San Diego: Academic Press, 19: 275-287, 1999.
19. Risteli, J., Sassi, M-L., Eriksen, H., Niemi, S., Mansell, J. P., and Risteli, L. Epitope of the assay for the carboxyterminal telopeptide of human type I collagen (ICTP). J. Bone Min. Res., 12 (Suppl. 1): S498, 1997.
20. Oxlund, H., Mosekilde, L., and Oxtoft, G. Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Bone, 19: 479-484, 1996.
21. Kauppila, S., Bode, M. K., Stenbäck, F., Risteli, L., and Risteli, J. Cross-linked telopeptides of type I and III collagens in malignant ovarian tumors in vivo. Br. J. Cancer, in press, 1999.
22. Zhu, G-G., Melkko, J., Risteli, J., Kauppila, A., and Risteli, L. Differential processing of type I and type III procollagens in the tumor cysts and peritoneal ascitic fluid of patients with benign and malignant ovarian tumors. Clin. Chim. Acta, 229: 87-97, 1994.
23. Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., and Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (Lond.), 284: 67-68, 1980.
24. Liotta, L. A. Tumor invasion and metastases: role of extracellular matrix, Rhoads memorial award lecture. Cancer Res., 46: 1-7, 1986.
25. van den Hooff, A. Connective tissue as an active participant in the process of malignant growth. Anticancer Res., 6: 775-780, 1986.
26. Aznavoorian, S., Murphy, A. N., Stetler-Stevenson, W. G., and Liotta, L. A. Molecular aspects of tumor cell invasion and metastasis. Cancer (Phila.), 71: 1368-1483, 1993.
27. Furcht, L. T., Skubitz, A. P. N., and Fields, G. B. Tumor cell invasion, matrix metalloproteinases, and the dogma. Lab. Invest., 70: 781-783, 1994.
28. Stetler-Stevenson, W. G. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am. J. Pathol., 148: 1345-1350, 1996.
29. Autio-Harmainen, H., Karttunen, T., Hurskainen, T., Häyhtyä, M., Kauppila, A., and Tryggvason, K. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab. Invest., 69: 312-321, 1993.
30. Davidson, N. G. P., Khanna, S., Kirwan, P. H., and Bircumshaw, D. Prechemotherapy serum CA 125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin. Oncol., 3: 32-36, 1991.
31. Nagele, F., Petru, E., Medl, M., Kainz, C., Graf, A. H., and Sevelda, P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet. Gynecol., 86: 259-264, 1995.
32. Puls, L. E., Duniho, T., Hunter, J. E., Kryscio, R., Blackhurst, D., and Gallion, H. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol. Oncol., 61: 109-112, 1996.
33. Ind, T., Iles, R., Shepherd, J., and Chard, T. Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen, and free β human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer. Br. J. Obstet. Gynaecol., 104: 1024-1029, 1997.
34. Einhorn, N., Nilsson, B., and Sjävall, K. Factors influencing survival in carcinoma of the ovary. Cancer (Phila.), 55: 2019-2025, 1985.
35. Balvert-Locht, H. R., Coebergh, J-W. W., Hop, W. C. J., Brälmann, H. A. M., Crommelin, M., van Wijck, D. J. A. M., and Verhagen-Teulings, M. T. C. I. J. Improved prognosis of ovarian cancer in the Netherlands during the period 1975-1985: a registry-based study. Gynecol. Oncol., 42: 3-8, 1991.
36. Yedema, C. A., Kenemans, P., Voorhorst, F., Bon, G., Schijf, C., Beex, L., Verstraeten, A., Hilgers, J., and Vermorken, J. CA 125 half-life in ovarian cancer: a mulrivariate survival analysis. Br. J. Cancer. 67: 1361-1367, 1993.
37. Sigurdsson, K., Alm, P., and Gullberg, B. Prognostic factors in malignant epithelial ovarian tumors. Gynecol. Oncol., 15: 370-380, 1983.
38. Hartenbach, E. M., Olson, T. A., Goswitz, J. J., Mohanraj, D., Twiggs, L. B., Carson, L. F., and Ramakrishnan, S. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett., 121: 169-175, 1997.